Weekly Digest - March 2025
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - March 2025
10 Mar 2025: Immunome doses first patient in Phase 1 trial of IM-1021, a ROR1-targeted ADC
- Immunome, Inc. has initiated the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC, with the first patient dosed
- The trial aims to establish the safety and explore the efficacy of IM-1021 in patients with high unmet needs, particularly those with B-cell lymphomas and solid tumors
- IM-1021 is an optimized ADC that includes Immunome’s proprietary TOP1 inhibitor, HC74
- The Phase 1 trial is an open-label, multicenter study designed to assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in advanced cancer patients
